Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

Table 3 Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves. Characterization of Dementia Incidence in the Statin Groups and CV Comparator

		Dementia cases		Time to incidence for dementia cases (months)		Time to end of study for non-dementia cases (months)
Drug	Sample size (n)	n	%	Mean	SD	Mean	SD	Model 3: HR for incidence of dementia vs CV (95% CI)
CV	394 739	3359	0.85	19.8	8.0	30.3	8.6
Atorvastatin	53 869	275	0.51	19.5	7.7	23.9	11.6	0.91 (0.80–1.02)
Lovastatin	54 052	439	0.81	19.1	7.9	29.7	8.1	0.95 (0.86–1.05)
Simvastatin	727 128	2647	0.36	19.3	7.8	29.1	8.0	0.46 (0.44–0.48)

CV, cardiovacular.
Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 4, percentage of dementia cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period and point at which subjects not receiving a diagnosis of dementia were censored due to the end of the analytic period, and SD.
Hazard ratio for incidence of dementia based on the results from model 3 (Table 2).

ISSN: 1741-7015